BCART Stock Overview
A molecular diagnostics company, provides diagnostic solutions enhancing clinical practice for the benefit of patients, clinicians, payers, and healthcare industry with a focus on oncology. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Biocartis Group NV Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.29 |
| 52 Week High | €0 |
| 52 Week Low | €0 |
| Beta | 1.33 |
| 11 Month Change | 0% |
| 3 Month Change | 0% |
| 1 Year Change | 0% |
| 33 Year Change | -92.28% |
| 5 Year Change | -95.33% |
| Change since IPO | -97.77% |
Recent News & Updates
Recent updates
Investors Give Biocartis Group NV (EBR:BCART) Shares A 31% Hiding
Jun 17
Analysts Have Been Trimming Their Biocartis Group NV (EBR:BCART) Price Target After Its Latest Report
Feb 27We Think Biocartis Group (EBR:BCART) Has A Fair Chunk Of Debt
Mar 03What Kind Of Shareholders Own Biocartis Group NV (EBR:BCART)?
Jan 27What We Learned About Biocartis Group's (EBR:BCART) CEO Compensation
Dec 06What Can We Learn About Biocartis Group's (EBR:BCART) CEO Compensation?
Sep 01What Type Of Returns Would Biocartis Group's(EBR:BCART) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?
Jul 28
Shareholder Returns
| BCART | BE Medical Equipment | BE Market | |
|---|---|---|---|
| 7D | 0% | -0.2% | -1.6% |
| 1Y | 0% | 10.6% | 2.0% |
Return vs Industry: BCART underperformed the Belgian Medical Equipment industry which returned 12.3% over the past year.
Return vs Market: BCART underperformed the Belgian Market which returned 2.7% over the past year.
Price Volatility
| BCART volatility | |
|---|---|
| BCART Average Weekly Movement | 0% |
| Medical Equipment Industry Average Movement | 6.1% |
| Market Average Movement | 3.3% |
| 10% most volatile stocks in BE Market | 6.3% |
| 10% least volatile stocks in BE Market | 2.1% |
Stable Share Price: Data is not available.
Volatility Over Time: Insufficient data to determine BCART's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 526 | Roger Moody | www.biocartisgroupnv.be |
Biocartis Group NV, a molecular diagnostics company, provides diagnostic solutions enhancing clinical practice for the benefit of patients, clinicians, payers, and healthcare industry with a focus on oncology. Its proprietary molecular diagnostics Idylla platform is a real-time polymerase chain reaction system that offers molecular information that allows treatment selection and treatment progress monitoring. The company offers Idylla BRAF, KRAS, MSI, EGFR, and NRAS-BRAF mutation tests; and Idylla SARS-CoV-2/Flu/RSV panels and SARS-CoV-2 tests, as well as SeptiCyte RAPID, a rapid host-response test.
Biocartis Group NV Fundamentals Summary
| BCART fundamental statistics | |
|---|---|
| Market cap | €27.24m |
| Earnings (TTM) | -€67.87m |
| Revenue (TTM) | €60.82m |
0.4x
P/S Ratio-0.4x
P/E RatioIs BCART overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BCART income statement (TTM) | |
|---|---|
| Revenue | €60.82m |
| Cost of Revenue | €65.51m |
| Gross Profit | -€4.69m |
| Other Expenses | €63.18m |
| Earnings | -€67.87m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.72 |
| Gross Margin | -7.71% |
| Net Profit Margin | -111.58% |
| Debt/Equity Ratio | -257.9% |
How did BCART perform over the long term?
See historical performance and comparison